High-Purity Ethyl 4-(1-hydroxy-1-methylethyl)-2-propyl-imidazole-5-carboxylate Manufacturer | Pharmaceutical Intermediate Supplier in China

Discover a premier supplier for Ethyl 4-(1-hydroxy-1-methylethyl)-2-propyl-imidazole-5-carboxylate (CAS: 144689-93-0), a crucial intermediate for Olmesartan medoxomil synthesis. We offer high-quality, reliably sourced pharmaceutical intermediates with competitive pricing and excellent technical support for global pharmaceutical manufacturers.

Get a Quote & Sample

Advantages of Sourcing Our Pharmaceutical Intermediates

Consistent Quality Assurance

Our manufacturing processes adhere to strict quality control measures, ensuring every batch of Ethyl 4-(1-hydroxy-1-methylethyl)-2-propyl-imidazole-5-carboxylate meets global pharmaceutical standards.

Expert Technical Support

Leverage our extensive knowledge in chemical synthesis. We provide comprehensive technical data, including COA, MOA, and MSDS, to support your R&D and production.

Global Supply Chain Capabilities

We are a reliable chemical supplier with a strong global distribution network, ensuring timely delivery of pharmaceutical intermediates like CAS 144689-93-0 to your facility, anywhere in the world.

Key Application in Pharmaceutical Synthesis

Olmesartan Medoxomil Synthesis

The primary application of Ethyl 4-(1-hydroxy-1-methylethyl)-2-propyl-imidazole-5-carboxylate is as a key intermediate in the multi-step synthesis of Olmesartan medoxomil, a vital medication for managing hypertension.

API Intermediate Manufacturing

This compound serves as a critical building block in the broader field of Active Pharmaceutical Ingredient (API) manufacturing, contributing to the development of essential medicines.

Fine Chemical Synthesis

Its unique imidazole structure makes it valuable in fine chemical synthesis for various research and development purposes in the pharmaceutical sector.

Research & Development

Used by R&D scientists and formulators to explore new synthetic pathways and optimize existing processes for novel drug candidates, supporting innovation in the pharmaceutical industry.